Brian J. Parks

Researcher

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

3 h-index 12 pubs 32 cited

Research Areas

Links

Research Group

OverviewAI-generated summary

Brian J. Parks conducts research focused on substance-related disorders and the effects of various substances on animal models, particularly in relation to pregnancy and early life adversity. His work investigates the pharmacological properties of substances like buprenorphine, including its metabolism and interactions, and explores the impact of environmental factors, such as limited bedding and nesting, on ethanol consumption in female rats. Parks also examines public perceptions and motives related to substances like kratom, analyzing responses to regulatory inquiries. His research has involved studies on the effects of early life adversity models on adolescent ethanol self-administration and adrenergic receptor expression. Collaborations with colleagues at the University of Arkansas for Medical Sciences, including Lisa K. Brents and Julia Tobacyk, have resulted in multiple shared publications. Parks' scholarship metrics include an h-index of 3, with 12 total publications and 29 total citations.

Metrics

h-index: 3
Publications: 12
Citations: 32

Selected Publications

Development and Psychometric Evaluation of a Theory-Based Preceptorship Survey for Nurse Practitioners (2025)

DOI OpenAlex
Limited bedding and nesting increases ethanol drinking in female rats (2024)

8 citations DOI OpenAlex
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome (2023)

2 citations DOI OpenAlex
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)

4 citations DOI OpenAlex
Effects of a two-hit model of early life adversity on oral ethanol self-administration and adrenergic receptor expression in adolescent rats (2023)

DOI OpenAlex
481 Interactions between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome (2023)

DOI OpenAlex
Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome. (2022)

DOI OpenAlex
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2022)

DOI OpenAlex
Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom (2022)

14 citations DOI OpenAlex
Effects of prenatal opioid exposure and early life adversity on opioid‐induced antinociception (2022)

DOI OpenAlex
384 Motives for kratom self-medication: contents of public comments solicited by the FDA (2022)

1 citation DOI OpenAlex